Results 221 to 230 of about 421,641 (311)

Myelitis‐Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late‐Onset Neuromyelitis Optica Spectrum Disorders

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare clinical features and prognosis of late‐onset neuromyelitis optica spectrum disorder (LO‐NMOSD, onset age ≥60 years) with adult‐onset NMOSD (AO‐NMOSD, onset age 18–59 years), and to provide insights for individualized management in elderly patients.
Ya‐Lan Pu, Jin‐Zhou Feng, Hua‐Xing Meng, Hai‐Bing Xiao, Xiao‐Ling Li, Jin Zhen, Wen‐Ying Lu, Xu‐Ming Xi, Ti Wu, Bao‐Shi Yuan, Mo‐Li Fan, Chao Zhang, De‐Cai Tian, Xia Meng, Fu‐Dong Shi, Tian Song   +15 more
wiley   +1 more source

Nanoparticle‐Based Tolerogenic Vaccines: Next‐Generation Strategies for Autoimmune and Allergic Disease Therapies

Angewandte Chemie, EarlyView.
Nanoparticle‐based tolerogenic vaccines harness controlled antigen delivery and immunomodulation to establish tolerance in autoimmunity and allergy. This review outlines how nanoparticle design (size, shape, composition, administration route) influences biodistribution and immune‐cell targeting.
Benjamin E. Nachod, Ajay S. Thatte, Rohan Palanki, Michael J. Mitchell   +3 more
wiley   +2 more sources

The Effects of Aquatic Therapy on Depression, Fatigue, and Balance in Patients with Multiple Sclerosis (MS): a Systematic Review and Meta-Analysis. [PDF]

Maedica (Bucur)
Naeimi N, Rastkar M, Shahraki A, Abdi M, Ghajarzadeh M.   +4 more
europepmc   +1 more source

Brain Atrophy Associated With Risk Variant rs10191329 Extends Beyond Multiple Sclerosis

Annals of Neurology, EarlyView.
The risk allele rs10191329*A is associated with disease severity and brain atrophy in people with multiple sclerosis (MS). We investigated the association of rs10191329 with age‐related brain atrophy in a population‐based cohort using 10,308 magnetic resonance imaging (MRI) scans of 4,815 participants aged ≥ 45 years without MS in cross‐sectional and ...
Cato E. A. Corsten, Ana M. Marques, Elisabeth J. Vinke, C. Louk de Mol, Rinze F. Neuteboom, M. Kamran Ikram, Mohsen Ghanbari, Frank J. Wolters, Beatrijs Wokke, Meike W. Vernooij, Joost Smolders   +10 more
wiley   +1 more source

Prevalence of cognitive impairment (CI) in patients with multiple sclerosis (MS): A systematic review and meta-analysis. [PDF]

Caspian J Intern Med
Askari M, Mirmosayyeb O, Fattahi F, Ghoshouni H, Moases Ghaffary E, Shaygannejad V, Ghajarzadeh M.   +6 more
europepmc   +1 more source

Confined B‐Cell Reconstruction and High T‐Cell Clonality Define Clinical Response to Cladribine Treatment

Annals of Neurology, EarlyView.
Cladribine tablets are approved for relapsing multiple sclerosis, mediating their clinical effect by moderately depleting lymphocytes. In a prospective, monocentric study including 22 patients completing 2 annual cycles of cladribine, B‐ and T‐cell receptor repertoires and relapse activity were assessed at baseline and after 24 months. T‐cell clonality
Tilman Schneider‐Hohendorf, Maria Eveslage, Timo Wirth, Christian Wünsch, Eva M. Schumann, Jan D. Lünemann, Heinz Wiendl, Luisa Klotz, Nicholas Schwab   +8 more
wiley   +1 more source

Insights into the interplay between Epstein-Barr virus (EBV) and multiple sclerosis (MS): A state-of-the-art review and implications for vaccine development. [PDF]

Health Sci Rep
Mohammadzamani M, Kazemzadeh K, Chand S, Thapa S, Ebrahimi N, Yazdan Panah M, Shaygannejad V, Mirmosayyeb O.   +7 more
europepmc   +1 more source

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Annals of Neurology, 2005
C. Polman, S. Reingold, G. Edan, M. Filippi, H. Hartung, L. Kappos, F. Lublin, L. Metz, H. McFarland, P. O'Connor, M. Sandberg-wollheim, A. Thompson, B. Weinshenker, J. Wolinsky   +13 more
semanticscholar   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications. [PDF]

Pharmacoeconomics
Campbell JA, Henson GJ, Ngwa VF, Ahmad H, Taylor BV, van der Mei I, MSBase Australian Researchers, Palmer AJ.   +7 more
europepmc   +1 more source